Antibody-drug conjugates in breast cancer: current evidence and future directions
Abstract Antibody-drug conjugates (ADCs) are a rapidly evolving class of antitumor drugs and have already revolutionized the treatment strategy of many hematologic and solid cancers. So far, trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG) and datopotamab der...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2025-03-01
|
| Colección: | Experimental Hematology & Oncology |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s40164-025-00632-9 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|